Back to top
more

Stryker (SYK)

(Delayed Data from NYSE)

$328.45 USD

328.45
1,589,324

+1.82 (0.56%)

Updated May 3, 2024 04:00 PM ET

After-Market: $328.52 +0.07 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Align Technology (ALGN) Gains From Innovation, Macro Issues Ail

by Zacks Equity Research

In terms of innovation, Align Technology successfully launched its first subscription-based clear aligner program Doctor Subscription Program (DSP) worldwide.

Here's Why Investors Should Retain Abbott (ABT) Stock Now

by Zacks Equity Research

Investors are optimistic about Abbott (ABT), led by solid prospects in the Diagnostic business and robust adoption of FreeStyle Libre.

Edwards Lifesciences (EW) Up 21.8% YTD: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifescience's (EW) substantial growth across each of its four product groups.

Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100

by Zacks Equity Research

The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Product innovations and strategic progress bode well for Tandem Diabetes (TNDM).

Chemed (CHE) Reaches a New 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Chemed (CHE) on strong performance across the VITAS and Roto-Rooter segments.

Labcorp (LH) Presents New Research on Precision Diagnostics

by Zacks Equity Research

Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.

Boston Scientific (BSX) Global Growth Robust, Macro Issues Ail

by Zacks Equity Research

Boston Scientific (BSX) is consistently registering fast recovery within its MedSurg segment in the post-pandemic period.

PetIQ (PETQ) Broadens Minties Line With Large Dogs Dental Treats

by Zacks Equity Research

PetIQ (PETQ), with a focus on affordability and natural ingredients, is well-positioned to meet the evolving needs of pet owners and continue its growth trajectory in the pet wellness market.

Here's Why You Should Buy Insulet (PODD) Stock Right Now

by Zacks Equity Research

Investors remain confident in the Insulet (PODD) stock due to the huge success of Omnipod 5.

Exact Sciences' (EXAS) BLUE-C Study Results Published in NEJM

by Zacks Equity Research

Exact Sciences (EXAS) announces the publication of the BLUE-C study results in The New England Journal of Medicine.

Edwards Lifesciences (EW) Hits 52-Week High: What's Driving It?

by Zacks Equity Research

Edwards Lifesciences (EW) outperforms the industry, owing to a robust 2023 fourth-quarter performance, as well as the strong potential in the TMTT division.

Charles River (CRL) Extends Gene Therapy Offering With New Pact

by Zacks Equity Research

Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.

Labcorp (LH) Expands Strategic Alliances, Test Sales Fall

by Zacks Equity Research

Labcorp (LH) continues to progress in terms of integrating hospital partnerships and acquisitions.

Envista (NVST) Faces Macroeconomic Challenges, FX Headwind

by Zacks Equity Research

The challenging macroeconomic conditions are resulting in a significant escalation in Envista's (NVST) costs and expenses.

Inspira Technologies (IINN) Releases Favorable Data on VORTX

by Zacks Equity Research

Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.

Here's Why You Should Retain Charles River (CRL) Stock Now

by Zacks Equity Research

Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.

Bruker (BRKR) Up 20.7% Since Last Earnings: What's Driving It?

by Zacks Equity Research

Investors are upbeat about Bruker (BRKR) led by strong NANO group prospects and strong guidance.

Chemed's (CHE) VITAS Segment Inks New Deal With Covenant Care

by Zacks Equity Research

Chemed's (CHE) VITAS segment is set to acquire the hospice assets of Covenant Care in Florida and Alabama.

Here's Why You Should Retain Globus Medical (GMED) Stock Now

by Zacks Equity Research

Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.

Edwards Lifesciences' (EW) SAPIEN TAVR Study Outcome Favorable

by Zacks Equity Research

Edwards Lifesciences' (EW) recent study provides insights into the actual performance of small Edwards valves and reaffirms the excellent outcomes for patients receiving SAPIEN TAVR.

Alcon's (ALC) New Launch Strengthens IOL Innovation Leadership

by Zacks Equity Research

Alcon's (ALC) Clareon platform is available in India in two PCIOL technologies, PanOptix and Vivity.

Integra LifeSciences (IART) Introduces MicroMatrix Flex

by Zacks Equity Research

Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.

Bio-Rad (BIO) Suffers due to BioPharma Softness, Stiff Competition

by Zacks Equity Research

Bio-Rad's (BIO) margin performance gets affected by the inflationary trend of elevated raw material costs, increased logistics costs and higher employee-related expenses.

KORU Medical (KRMD) Forms New Deal on Subcutaneous Infusion

by Zacks Equity Research

One key aspect of the collaboration of KORU Medical (KRMD) with a pharmaceutical manufacturer is the exploration of new therapeutic settings.